The role of autologous bone marrow transplantation in primary effusion lymphoma: a case report and literature review

IF 1.6 Q3 HEMATOLOGY Hematology, Transfusion and Cell Therapy Pub Date : 2024-12-01 Epub Date: 2024-07-23 DOI:10.1016/j.htct.2024.04.119
Vitor Abreu de Goes , Anita Cassoli Cortez , Diogo Lago Morbeck , Felipe D'Almeida Costa , Talita Bueno da Silveira
{"title":"The role of autologous bone marrow transplantation in primary effusion lymphoma: a case report and literature review","authors":"Vitor Abreu de Goes ,&nbsp;Anita Cassoli Cortez ,&nbsp;Diogo Lago Morbeck ,&nbsp;Felipe D'Almeida Costa ,&nbsp;Talita Bueno da Silveira","doi":"10.1016/j.htct.2024.04.119","DOIUrl":null,"url":null,"abstract":"<div><div>Primary effusion lymphoma (PEL) is an aggressive and rare type of diffuse large B-cell lymphoma (DLBL) that commonly presents itself as pleural, pericardial or peritoneal effusion without lymph node or extranodal involvement in immunosuppressed patients, such as HIV-positive or transplanted receptors. On rare occasions, it may be found in solid sites without effusion, in an immunophenotypically and morphologically similar neoplasm well-known as extracavitary PEL (EC-PEL). Both PEL and EC-PEL are associated with extremely poor prognosis. Due to the rarity of these entities, ther e are no gold standard treatments . Here we discuss the role of autologous bone marrow transplant (auto-BMT) in the treatment of these patients as well as report the case of a young HIV-positive male diagnosed with both PEL and EC-PEL, who underwent a salvage therapy with auto-BMT and achieved complete and sustained remission eight years after the diagnosis.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"46 ","pages":"Pages S316-S321"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137924002736","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Primary effusion lymphoma (PEL) is an aggressive and rare type of diffuse large B-cell lymphoma (DLBL) that commonly presents itself as pleural, pericardial or peritoneal effusion without lymph node or extranodal involvement in immunosuppressed patients, such as HIV-positive or transplanted receptors. On rare occasions, it may be found in solid sites without effusion, in an immunophenotypically and morphologically similar neoplasm well-known as extracavitary PEL (EC-PEL). Both PEL and EC-PEL are associated with extremely poor prognosis. Due to the rarity of these entities, ther e are no gold standard treatments . Here we discuss the role of autologous bone marrow transplant (auto-BMT) in the treatment of these patients as well as report the case of a young HIV-positive male diagnosed with both PEL and EC-PEL, who underwent a salvage therapy with auto-BMT and achieved complete and sustained remission eight years after the diagnosis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
自体骨髓移植在原发性渗出淋巴瘤中的作用:病例报告和文献综述
原发性积液性淋巴瘤(PEL)是一种侵袭性、罕见的弥漫性大b细胞淋巴瘤(DLBL),通常表现为胸膜、心包或腹膜积液,在免疫抑制患者(如hiv阳性或移植受体)中无淋巴结或结外浸润。在极少数情况下,它可以在没有积液的实体部位发现,在免疫表型和形态相似的肿瘤中被称为腔外PEL (EC-PEL)。PEL和EC-PEL均伴有极差的预后。由于这些实体的稀有性,没有黄金标准治疗。在这里,我们讨论自体骨髓移植(auto-BMT)在治疗这些患者中的作用,并报告一名诊断为PEL和EC-PEL的年轻hiv阳性男性病例,他接受了自体骨髓移植的挽救治疗,并在诊断后8年实现了完全和持续的缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.40
自引率
4.80%
发文量
1419
审稿时长
30 weeks
期刊最新文献
Exploring the prognostic impact and biological functions of mutant-like TP53-related genes in acute myeloid leukemia Atypical chronic lymphocytic leukemia with biallelic 13Q deletion Therapeutic plasma exchange in acute liver failure: Unravelling its efficacy and impact Bridging the clinical equivalence gap: a nationwide survey on healthcare professionals' perceptions of whole blood-derived versus apheresis platelets in China Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1